Literature DB >> 34262618

Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care.

Lei Huang1, Lina Jansen2, Rob H A Verhoeven3, Jelle P Ruurda4, Liesbet Van Eycken5, Harlinde De Schutter5, Jan Johansson6, Mats Lindblad7, Tom B Johannesen8, Vesna Zadnik9, Tina Žagar9, Margit Mägi10, Sjoerd M Lagarde11, Esther Bastiaannet12, Cornelis J H van de Velde12, Petra Schrotz-King13, Hermann Brenner14.   

Abstract

AIMS: The role of resection remains debated in cases of metastatic gastric carcinoma (mGC). Some mGCs are technically resectable. At the population level, the real-world application of resection for mGC remains largely unclear in most Western countries. This large, population-based international investigation aimed to reveal the resection patterns and trends for mGC and the treatment-associated factors in Europe and the US.
METHODS: Data on cases with microscopically-confirmed primary invasive stomach carcinoma with distant metastasis were obtained from the nationwide cancer registries of the Netherlands, Belgium, Norway, Sweden, Estonia, and Slovenia and the US Surveillance, Epidemiology, and End Results-18 database. We calculated age-standardized rates of primary cancer-directed resection and assessed resection trends using linear regression. We investigated associations of treatment with patient and cancer factors using multivariable-adjusted log-binomial regression.
RESULTS: Among 133,321 patients with gastric cancer, overall, 40,215 cases with mGC diagnosed between 2003-2017 were investigated. Age-standardized resection rates significantly declined over time in the US, Belgium, Sweden, and Norway (by 5-14%). Resection rates greatly differed from 5% to 16% in 2013-2014. Cases with older ages, cardia tumors, or tumors involving adjacent structures were significantly less often operated across most countries. Sex was not significantly associated with resection. Across countries the association patterns and strengths differed largely. With multivariable adjustment, resection rates decreased significantly in all countries except Slovenia and Estonia (prevalence ratio per year = 0.90-0.98), and the decreasing trends were consistently observed in various stratifications by age and location.
CONCLUSION: In Europe and the US, resection patterns and trends largely varied across countries for mGCs, which were mostly less often resected in the early 21st century. Various resection-associated factors were shown, with greatly varying association patterns and strengths. Our report could aid to identify discrepancies in clinical practice and highlight the great need for further clarifying the role of resection in mGCs to enhance standardization of care.
© The Author(s), 2021.

Entities:  

Keywords:  great variations; large international population-based investigation; metastatic gastric carcinoma; patterns and trends; treatment

Year:  2021        PMID: 34262618      PMCID: PMC8243140          DOI: 10.1177/17588359211027837

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN: 1758-8340            Impact factor:   8.168


  35 in total

1.  The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study.

Authors:  Mathieu Messager; Jérémie H Lefevre; Virginie Pichot-Delahaye; Amine Souadka; Guillaume Piessen; Christophe Mariette
Journal:  Ann Surg       Date:  2011-11       Impact factor: 12.969

2.  Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial.

Authors:  Mitsuru Sasako; Takeshi Sano; Seiichiro Yamamoto; Motonori Sairenji; Kuniyoshi Arai; Taira Kinoshita; Atsushi Nashimoto; Masahiro Hiratsuka
Journal:  Lancet Oncol       Date:  2006-08       Impact factor: 41.316

Review 3.  The diagnosis and management of gastric cancer.

Authors:  Sri G Thrumurthy; M Asif Chaudry; Daniel Hochhauser; Muntzer Mughal
Journal:  BMJ       Date:  2013-11-04

4.  Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.

Authors:  Udo Rudloff; Russell C Langan; John E Mullinax; Joal D Beane; Seth M Steinberg; Tatiana Beresnev; Carole C Webb; Melissa Walker; Mary Ann Toomey; David Schrump; Prakash Pandalai; Alexander Stojadinovic; Itzhak Avital
Journal:  J Surg Oncol       Date:  2014-07-05       Impact factor: 3.454

5.  Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?

Authors:  Ulrike Heger; Susanne Blank; Christiane Wiecha; Rupert Langer; Wilko Weichert; Florian Lordick; Thomas Bruckner; Martin Dobritz; Maria Burian; Christoph Springfeld; Lars Grenacher; Jörg-Rüdiger Siewert; Markus Büchler; Katja Ott
Journal:  Ann Surg Oncol       Date:  2014-01-14       Impact factor: 5.344

6.  Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy.

Authors:  Yaniv Berger; Mihai Giurcanu; Charles C Vining; Darryl Schuitevoerder; Mitchell C Posner; Kevin K Roggin; Blase N Polite; Chih-Yi Liao; Oliver S Eng; Daniel V T Catenacci; Kiran K Turaga
Journal:  Ann Surg Oncol       Date:  2021-01-08       Impact factor: 5.344

7.  Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients.

Authors:  James J Mezhir; Manish A Shah; Lindsay M Jacks; Murray F Brennan; Daniel G Coit; Vivian E Strong
Journal:  Ann Surg Oncol       Date:  2010-06-29       Impact factor: 5.344

8.  The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation.

Authors:  Nikolaos Charalampakis; Graciela M Nogueras González; Elena Elimova; Roopma Wadhwa; Hironori Shiozaki; Yusuke Shimodaira; Mariela A Blum; Jane E Rogers; Kazuto Harada; Aurelio Matamoros; Tara Sagebiel; Prajnan Das; Bruce D Minsky; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Jeannelyn S Estrella; Brian D Badgwell; Jaffer A Ajani
Journal:  Oncology       Date:  2016-04-06       Impact factor: 2.935

9.  The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.

Authors:  Sid P Kerkar; Clinton D Kemp; Austin Duffy; Udai S Kammula; David S Schrump; King F Kwong; Martha Quezado; Barry R Goldspiel; Aradhana Venkatesan; Ann Berger; Melissa Walker; Mary Ann Toomey; Seth M Steinberg; Guiseppe Giaccone; Steven A Rosenberg; Itzhak Avital
Journal:  Trials       Date:  2009-12-23       Impact factor: 2.279

View more
  3 in total

1.  Bone Metastasis From Gastric Adenocarcinoma-What Are the Risk Factors and Associated Survival? A Large Comprehensive Population-Based Cohort Study.

Authors:  Lei Huang; Yajie Zhao; Yan Shi; Weiguo Hu; Jun Zhang
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

2.  Survival trends of patients with non-metastatic gastric adenocarcinoma in the US and European countries: the impact of decreasing resection rates.

Authors:  Lei Huang; Lina Jansen; Rob H A Verhoeven; Jelle P Ruurda; Liesbet Van Eycken; Harlinde De Schutter; Jan Johansson; Mats Lindblad; Tom B Johannesen; Vesna Zadnik; Tina Žagar; Sjoerd M Lagarde; Cornelis J H van de Velde; Petra Schrotz-King; Hermann Brenner
Journal:  Cancer Commun (Lond)       Date:  2022-06-06

3.  Editorial: The use of chemotherapy in treating gastric cancers.

Authors:  Lei Huang; Yan Shi
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.